Table 5 Mental health and social functioning among trial participants over six months
From: Severe COVID anxiety among adults in the United Kingdom: cohort study and nested feasibility trial
Measure | Allocation arm | Baseline mean | 3Â months | 6Â months | Mean difference baseline to 6Â months [95% CI] |
|---|---|---|---|---|---|
Coronavirus Anxiety Scale | Intervention | 12.05 | 7.47 | 5.05 | 7.0 [4.6, 9.4] |
Control | 12.32 | 8.87 | 6.38 | 5.94 [3.3, 8.6] | |
Depression (PHQ-9) | Intervention | 17.05 | 9.59 | 9.20 | 7.85 [5.1, 10.6] |
Control | 14.26 | 12.67 | 12.94 | 1.33 [-3.2, 5.9] | |
Anxiety (GAD-7) | Intervention | 16.57 | 11.53 | 9.55 | 7.02 [4.4, 9.6] |
Control | 15.84 | 13.53 | 12.44 | 3.40 [-0.5, 7.3] | |
Health anxiety (sHAI) | Intervention | 27.33 | 19.94 | 16.50 | 10.83 [7.6, 14.1] |
Control | 27.63 | 26.67 | 23.10 | 4.57 [-0.1, 9.2] | |
Social functioning (WSAS) | Intervention | 20.43 | 14.0 | 10.70 | 9.7 [5.8, 13.6] |
Control | 21.95 | 20.20 | 20.94 | 1.01 [-4.6, 6.6] |